PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
- Weitere Titel
-
PARP-Inhibitoren beim rezidivierenden Ovarialkarzinom, aktuelle Therapieoptionen und zukünftige Entwicklungen
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives ; volume:76 ; number:02 ; year:2016 ; pages:164-169
Geburtshilfe und Frauenheilkunde ; 76, Heft 02 (2016), 164-169
- Beteiligte Personen und Organisationen
-
Sehouli, J.
Braicu, E. I.
Chekerov, R.
- DOI
-
10.1055/s-0035-1558185
- URN
-
urn:nbn:de:101:1-2019011114175943962243
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 08:46 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sehouli, J.
- Braicu, E. I.
- Chekerov, R.
Ähnliche Objekte (12)
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma
PARP Inhibitors in Ovarian Cancer: A Review
Advances and perspectives of PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Surgery in recurrent ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma
PARP Inhibitors in Ovarian Cancer: A Review
Advances and perspectives of PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Surgery in recurrent ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma
PARP Inhibitors in Ovarian Cancer: A Review
Advances and perspectives of PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Surgery in recurrent ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer